OXiGENE Announces Fourth Quarter and Fiscal 2010 Earnings Conference Call and Webcast
February 28 2011 - 9:01AM
OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical
company developing novel therapeutics to treat cancer and eye
diseases, will report fourth quarter and fiscal year-end 2010
results, along with guidance for 2011, on Thursday, March 3, 2011.
A conference call and webcast hosted by OXiGENE management will
begin at 4:30 pm EST (1:30 p.m. PST).
To listen to a live or an archived version of the audio webcast,
please log on to the Company's website, www.oxigene.com. Under the
"Investors" tab, select the link to "Events &
Presentations."
OXiGENE's earnings conference call can also be heard live by
dialing (888) 841-3431 in the United States and Canada, and +1
(678) 809-1060 for international callers, five minutes prior to the
beginning of the call. A replay will be available starting at 7:30
p.m. EST, (4:30 p.m. PST) on March 3, 2011 and ending at midnight
EST (9:00 p.m. PST) on Wednesday, March 9, 2011. To access the
replay, please dial (800) 642-1687 if calling from the United
States or Canada, or +1 (706) 645-9291 from international
locations. Please refer to replay pass code 44782248.
About OXiGENE, Inc.
OXiGENE is a clinical-stage biotechnology company developing
novel small-molecule therapeutics to treat cancer and eye diseases.
The Company's major focus is the clinical advancement of drug
candidates that selectively disrupt abnormal blood vessels
associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property
position and therapeutic development expertise to bring life saving
and enhancing medicines to patients.
The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969
CONTACT: Michelle Edwards, Investor Relations
medwards@oxigene.com
650-635-7006
Oxigene, Inc. (MM) (NASDAQ:OXGND)
Historical Stock Chart
From Apr 2024 to May 2024
Oxigene, Inc. (MM) (NASDAQ:OXGND)
Historical Stock Chart
From May 2023 to May 2024